Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
NCT ID: NCT03755193
Last Updated: 2021-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
90 participants
INTERVENTIONAL
2018-11-24
2026-11-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis
NCT02306187
Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients
NCT02156960
Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
NCT00680953
Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese
NCT02166437
Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy
NCT03702140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SERM plus ELD
To examine the effects of SERM plus ELD in osteoporosis patients
SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"
To examine the effects of SERM and ELD in osteoporosis patients
Bisphosphonates and ELD "Edirol®Tablet 0.75ug"
To examine the effects of BP and ELD in osteoporosis patients
ELD "Edirol®Tablet 0.75ug"
To examine the effects of ELD in osteoporosis patients
BP plus ELD
To examine the effects of BP plus ELD in osteoporosis patients
SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"
To examine the effects of SERM and ELD in osteoporosis patients
Bisphosphonates and ELD "Edirol®Tablet 0.75ug"
To examine the effects of BP and ELD in osteoporosis patients
ELD "Edirol®Tablet 0.75ug"
To examine the effects of ELD in osteoporosis patients
ELD alone
To examine the effects of ELD alone in osteoporosis patients
SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"
To examine the effects of SERM and ELD in osteoporosis patients
Bisphosphonates and ELD "Edirol®Tablet 0.75ug"
To examine the effects of BP and ELD in osteoporosis patients
ELD "Edirol®Tablet 0.75ug"
To examine the effects of ELD in osteoporosis patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"
To examine the effects of SERM and ELD in osteoporosis patients
Bisphosphonates and ELD "Edirol®Tablet 0.75ug"
To examine the effects of BP and ELD in osteoporosis patients
ELD "Edirol®Tablet 0.75ug"
To examine the effects of ELD in osteoporosis patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shinshu University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yukio Nakamura
Lecturer at Shinshu University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yukio Nakamura
Matsumoto, Nagano, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DMAb switch 2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.